New drug duo offers hope for Tough-to-Treat lymphoma

NCT ID NCT05529069

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two oral drugs, pirtobrutinib and venetoclax, can control mantle cell lymphoma (MCL) in patients whose cancer has come back or hasn't responded to prior treatments. About 30 adults with confirmed MCL will take these pills to see how many achieve a significant reduction in cancer. The goal is disease control, not a cure, as ongoing management is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm mantle cell lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC MALIGNANCY MANTLE CELL LYMPHOMA NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.